Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
6960454
Reference Type
Journal Article
Title
GROWTH-HORMONE TREATMENT AND DIABETES - SURVEY OF THE KABI-PHARMACIA-INTERNATIONAL-GROWTH-STUDY
Author(s)
Czernichow, P; Albertssonwikland, K; Tuvemo, T; Gunnarsson, R; ,
Year
1991
Publisher
SCANDINAVIAN UNIVERSITY PRESS
Location
OSLO
Page Numbers
104-107
PMID
1815450
Web of Science Id
WOS:A1991HT05300015
Abstract
Out of a total of 8136 children registered in the Kabi Pharmacia International Growth Study, 12 have been reported to have diabetes either before or during treatment with growth hormone (GH). Two of these have non-insulin-dependent diabetes mellitus (NIDDM), of whom one had risk factors for the development of his condition, namely gross obesity and familial occurrence of NIDDM. One is a rare case of McCune-Albright's syndrome with insulin-dependent diabetes mellitus (IDDM), and 9 other patients have IDDM. Of these 9, 6 have idiopathic GH deficiency. In 8 of the 9 patients with IDDM, the condition was diagnosed before GH therapy was commenced, at ages ranging from less than 2 years to 16 years. The association is probably fortuitous, however, as the onset of IDDM in 7 patients was immediately before or during puberty, as often occurs in IDDM in general.
Conference Name
12TH INTERNATIONAL SYMP ON GROWTH AND GROWTH DISORDERS
Conference Location
GENEVA, SWITZERLAND
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity